Prostate cancer vaccine trial halted early – did it work?
NCT ID NCT02772562
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a vaccine called PROSTVAC-V/F in 33 men who had their prostate removed due to cancer and were at high risk of the cancer returning. The goal was to see if the vaccine could keep cancer from coming back. The study was stopped early, so results are limited, but it aimed to improve cancer control after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a better scan sharpen radiation for prostate cancer?
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can tracking tumor movement during radiation make treatment more precise?